JP2015501820A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501820A5
JP2015501820A5 JP2014546301A JP2014546301A JP2015501820A5 JP 2015501820 A5 JP2015501820 A5 JP 2015501820A5 JP 2014546301 A JP2014546301 A JP 2014546301A JP 2014546301 A JP2014546301 A JP 2014546301A JP 2015501820 A5 JP2015501820 A5 JP 2015501820A5
Authority
JP
Japan
Prior art keywords
compound
group
deuterated
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546301A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933746B2 (ja
JP2015501820A (ja
Filing date
Publication date
Priority claimed from CN2011104188590A external-priority patent/CN103159680A/zh
Application filed filed Critical
Publication of JP2015501820A publication Critical patent/JP2015501820A/ja
Publication of JP2015501820A5 publication Critical patent/JP2015501820A5/ja
Application granted granted Critical
Publication of JP5933746B2 publication Critical patent/JP5933746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546301A 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途 Active JP5933746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CN201110418859.0 2011-12-14
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Publications (3)

Publication Number Publication Date
JP2015501820A JP2015501820A (ja) 2015-01-19
JP2015501820A5 true JP2015501820A5 (enExample) 2015-04-23
JP5933746B2 JP5933746B2 (ja) 2016-06-15

Family

ID=48583248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546301A Active JP5933746B2 (ja) 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途

Country Status (9)

Country Link
US (1) US9346764B2 (enExample)
EP (1) EP2792674B1 (enExample)
JP (1) JP5933746B2 (enExample)
CN (2) CN103159680A (enExample)
AU (1) AU2012350482B2 (enExample)
CA (1) CA2859224C (enExample)
ES (1) ES2587903T3 (enExample)
PL (1) PL2792674T3 (enExample)
WO (1) WO2013087004A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014190895A1 (zh) * 2013-05-29 2014-12-04 成都海创药业有限公司 咪唑二酮类化合物及其用途
RU2016110546A (ru) * 2013-09-19 2017-10-24 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Комбинированная лекарственная терапия
CN105188699B (zh) * 2013-10-14 2017-04-26 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
KR102125661B1 (ko) 2017-02-13 2020-06-22 강푸 바이오파마슈티칼즈 리미티드 전립선암 치료용 조합, 약학 조성물 및 치료 방법
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
JP2021519322A (ja) * 2018-03-29 2021-08-10 ヒノバ ファーマシューティカルズ インコーポレイテッド 重水素化イミダゾリジンジオン化合物とその用途
US11753392B2 (en) 2018-04-13 2023-09-12 Hinova Pharmaceuticals Inc. Method for synthesis of deuterated amide and deuterated sulfonamide
AU2019268481B2 (en) * 2018-05-14 2025-04-03 Hinova Pharmaceuticals Inc. HC-1119 formulation, preparation method and use thereof
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
CN112442009B (zh) * 2019-08-30 2023-10-03 润佳(苏州)医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
WO2021185291A1 (zh) * 2020-03-17 2021-09-23 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
BR112023002295A2 (pt) 2020-08-13 2023-03-14 Pfizer Terapia de combinação
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特(成都)生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608436C (en) * 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) * 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
KR101456994B1 (ko) 2009-09-10 2014-11-04 통유지 안드로겐 수용체 길항제 및 그의 용도
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Similar Documents

Publication Publication Date Title
AU2018360854B2 (en) Modulators of the integrated stress pathway
RU2488582C2 (ru) Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение
JP2013543842A5 (enExample)
JP2013542261A5 (enExample)
JP2013032389A5 (enExample)
JP2010500343A5 (enExample)
RU2015149767A (ru) Дейтерированные диаминопиримидиновые соединения и фармацевтические композиции, содержащие такие соединения
JP2015537020A5 (enExample)
JP2014500861A5 (enExample)
JP2017524025A5 (enExample)
RU2015108898A (ru) 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
JP2015512943A5 (enExample)
JP2007515465A5 (enExample)
JP2009542613A5 (enExample)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2014500870A5 (enExample)
JP2011518833A5 (enExample)
IN2014KN00948A (enExample)
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
JP2014508752A5 (enExample)
JP2010529994A5 (enExample)
JP2018537535A5 (enExample)
JP2012512863A5 (enExample)
JP2011088926A5 (enExample)
JP2015500842A5 (enExample)